Cullinan Therapeutics Inc. is an early-stage biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company specializes in a range of innovative approaches including immuno-oncology and precision medicine. Its pipeline encompasses a variety of programs targeting defined mutations and tumor-specific mechanisms, aiming to deliver highly effective therapies with fewer side effects compared to traditional treatments. Cullinan Therapeutics Inc. operates within the biotechnology and healthcare sectors, playing a crucial role in advancing cancer treatment options through its novel and strategic drug development processes. By employing a diversified portfolio of therapeutic assets early in their development, the company seeks to address unmet medical needs across multiple cancer indications. This approach not only exemplifies Cullinan's commitment to innovation but also increases its significance in the market as a contributor to the expanding field of targeted cancer therapies.